Skip to main content
Medical information Clinical review pending

Genetic Testing

Cebpa Gene Leukemia Acute Myeloid Somatic Genetic Test

Detects mutations in the CEBPA gene associated with Acute Myeloid Leukemia (AML) using Next Generation Sequencing (NGS) technology. This test aids in diagnosis, treatment planning, and genetic counseling for AML.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
Results
Approximately 3 to 4 weeks. Confirm exact turnaround time with the laboratory before booking.
Preparation
No special preparation is typically required for a blood draw. Follow any specific instructions provided by the laboratory or your doctor.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Cebpa Gene Leukemia Acute Myeloid Somatic Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of Acute Myeloid Leukemia (AML)
  • ✓Risk stratification in AML patients
  • ✓Guiding treatment decisions for AML
  • ✓Identifying potential targets for therapy
  • ✓Genetic counseling for individuals with AML or family history
02

In plain language

What this test helps you understand

This test helps identify specific mutations in the CEBPA gene, which can influence the prognosis and treatment response in patients with Acute Myeloid Leukemia (AML). It provides valuable information for personalized medicine approaches and genetic counseling.
The CEBPA Gene Leukemia Acute Myeloid Somatic NGS Genetic DNA Test is a specialized diagnostic tool used to identify mutations within the CEBPA gene. These mutations are known to be associated with Acute Myeloid Leukemia (AML), a type of cancer affecting the blood and bone marrow. This test utilizes advanced Next Generation Sequencing (NGS) technology to analyze DNA samples, providing crucial information for healthcare providers. Understanding the genetic makeup of the leukemia can significantly impact treatment decisions and patient outcomes. This test is particularly important for individuals diagnosed with AML or suspected of having the condition based on clinical findings.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood draw. Follow any specific instructions provided by the laboratory or your doctor.
SampleBlood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the CEBPA gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific mutations in the CEBPA gene. It does not detect all possible genetic alterations associated with AML. Results should be interpreted in the context of clinical findings and other diagnostic tests. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The CEBPA gene provides instructions for making a protein involved in the development and function of blood cells. Mutations in this gene are associated with Acute Myeloid Leukemia (AML).
Identifying mutations in the CEBPA gene can help doctors understand the specific type of AML, predict how the disease might behave, and choose the most effective treatment plan.
Typically, a blood sample is required. In some cases, extracted DNA may be used. Please confirm the exact specimen requirements with the laboratory.
The estimated turnaround time is approximately 3 to 4 weeks. Please confirm the current turnaround time with the laboratory before booking.
Your doctor, often in consultation with a genetic counselor or oncologist, will interpret the results and discuss their implications with you.
Yes, genetic counseling is often recommended to help understand the test results, discuss potential risks for family members, and make informed decisions about treatment and future health management.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp